Marmé F, Solbach C, Michel L, et al. - Researchers sought to determine whether CPS + EG scoring system [based on pre-treatment clinical (CS) and post-treatment pathological stage (PS), oestrogen-receptor status (E) and grade (G)] offers a superior estimate of prognosis in triple-negative breast cancer (TNBC) to select candidates for postneoadjuvant therapy. This study involved 1795 patients with TNBC for whom the CPS + EG score was calculated. Findings showed inferior prognostic information was conferred by CPS + EG scoring in TNBC, vs the pathological stage, and also CPS + EG scoring failed to detect patients without pathological complete response (pCR) and with a sufficiently good prognosis, who could avoid postneoadjuvant therapy. In addition, pCR was revealed as the strongest and most clinically beneficial prognostic factor post-neoadjuvant chemotherapy. There is a requirement for other biologic factors beyond pCR in TNBC.